Literature DB >> 24413304

Surgery for tetralogy of Fallot - absent pulmonary valve syndrome. Technique of anterior translocation of the pulmonary artery.

Viktor Hraska1, Peter Murin, Joachim Photiadis, Nicodème Sinzobahamvya, Claudia Arenz, Boulos Asfour.   

Abstract

Patients with absent pulmonary valve syndrome (APVS) and tetralogy of Fallot represent a particular management's challenge. The distinctive feature of APVS is the airway obstruction caused by tracheobronchial compression that results from massive dilatation of the main pulmonary artery (PA) and its first- and second-order branches. Consequential tracheomalacia and bronchomalacia determine the timing and severity of respiratory compromise, as well as the morbidity and mortality of these patients. Although several techniques have been proposed for decompression of the airways, the method of choice is still controversial. Translocation of the PA anterior to the aorta and away from the airways has the potential to reduce or eliminate bronchial compression. Overall, the intermediate-term functional outcomes using this technique have been encouraging, with zero mortality even in the youngest age group of patients and the disappearance of respiratory symptoms in the majority of them. Nevertheless, failure of the treatment could be expected in symptomatic patients in whom the pathology of the airways extends beyond the proximal PAs.

Entities:  

Year:  2010        PMID: 24413304     DOI: 10.1510/mmcts.2008.003186

Source DB:  PubMed          Journal:  Multimed Man Cardiothorac Surg        ISSN: 1813-9175


  2 in total

1.  Bronchoscopic assessments and clinical outcomes in pediatric patients with tracheomalacia and bronchomalacia.

Authors:  Yuichi Okata; Tomomi Hasegawa; Yuko Bitoh; Kosaku Maeda
Journal:  Pediatr Surg Int       Date:  2017-11-09       Impact factor: 1.827

2.  Virtual 3D Modeling of Airways in Congenital Heart Defects.

Authors:  Simone Speggiorin; Saravanan Durairaj; Branko Mimic; Antonio F Corno
Journal:  Front Pediatr       Date:  2016-10-26       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.